Targeting neoantigens to augment antitumour immunity
By M. Yarchoan, Burles A. Johnson, Eric R. Lutz, D. Laheru, E. Jaffee. Nature Reviews. Cancer, 2017
867 citations recorded by the source corpus.
The past decade of cancer research has been marked by a growing appreciation of the role of immunity in cancer. Mutations in the tumour genome can cause tumours to express mutant proteins that are tumour specific and not expressed on normal cells (neoantigens). These neoantigens are an attractive immune target because their selective expression on tumours may minimize immune tolerance as well as the risk of autoimmunity. In this Review we discuss the emerging evidence that neoantigens are recognized by the immune system and can be targeted to increase antitumour immunity. We also provide a framework for personalized cancer immunotherapy through the identification and selective targeting of individual tumour neoantigens, and present the potential benefits and obstacles to this approach of targeted immunotherapy.
Subfields: Immunology, Oncology
View Paper: https://www.semanticscholar.org/paper/84586ee91f4473454d93183752e9aad7d884417f
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
In Oncology
Citations in the corpus
- Breast Cancer Immunotherapy: Facts and Hopes (2017, background): “The activated T-cell repertoire would thus include highavidity (stronger) T cells that can be effectively activated by vaccines to lyse tumor cells presenting these neoantigens (21).”
- Evaluation of machine learning methods to predict peptide binding to MHC Class I proteins (2017, background): “In particular, peptides that harbor somatic mutations specific to a patient’s tumor, known as neoantigens, can inform treatment [5] [6].”
- Cold Tumors: A Therapeutic Challenge for Immunotherapy (2019, background): “Tumor mutation burden (TMB) is a quantitative measure of the total number of mutations per coding area of a tumor genome that has been shown to predict responses to ICIs in a range of advanced cancers (10).”
- Advances in immunotherapy for hepatocellular carcinoma (2021, background): “I.M. receives funding from MINECO SAF2014-52361-R and SAF 2017- 83267-C2-1R; Worldwide Cancer Research Grant (15-1146); the Asociacion Española Contra el Cancer (AECC) Foundation under grant GCB15152947MELE; and the European Union’s Horizon 2020 Program (grant agreement no. 635122 PROCROP).”
- APP mouse models for Alzheimer's disease preclinical studies (2017, neutral): “Cancer stem cells arise in human bodies every day, but fail to develop into cancer in most cases because of cancer immunity (Yarchoan et It is important to perform delipidation pretreatment for the analysis of CTFs (Sato et al , 2003 ; Saito et al , 2014 ).”